Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies

Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies

© 2018 Saei et al. RAF kinase inhibitors are clinically active in patients with BRAF (V600E) mutant melanoma. However, rarely do tumors regress completely, with the majority of responses being short-lived. This is partially mediated through the loss of negative feedback loops after MAPK inhibition a...

Full description

Bibliographic Details
Main Authors: Saei, A., Palafox, M., Benoukraf, T., Kumari, N., Jaynes, P., Iyengar, P., Muñoz Couselo, E., Nuciforo, P., Cortés, J., Nötzel, C., Kumarakulasinghe, N., Richard, J., Isa, Z., Pang, B., Guzman, M., Siqin, Z., Yang, H., Tam, W., Serra, V., Eichhorn, Pieter
Format: Journal Article
Published: Rockefeller University Press 2018
Online Access:http://hdl.handle.net/20.500.11937/70928

Internet

http://hdl.handle.net/20.500.11937/70928

Similar Items